Healthcare Translation Research Group
The Healthcare Translation Group is focused on high-impact research in regenerative medicine (cell, gene, immuno-therapies and tissue engineering) and digital health – including medicines optimisation, supply chain security and implementation science/evaluation of digital technologies. This is complemented by research into critical enabling infrastructure including novel regulatory pathways, clinical adoption, biomanufacturing, reimbursement and intellectual property.
Advanced therapeutics clinical translation and cell therapy commercialisation
Advanced therapies, such as cell and gene therapies, are a new therapeutic modality which have potential to offer treatment or cures for currently untreatable diseases. This therapeutic strategy is very young in comparison to standard chemical-based drugs, and therefore few are currently established on the market.
Disease phenotype modeling
Mathematical modeling allows researchers to investigate the impact of certain therapeutic strategies on a hypothetical patient cohort, informing decision making.
Intellectual property landscaping
Intellectual property (IP) is of fundamental importance to medicinal product development. IP landscaping is a method by which information about IP can be gathered, and can provide valuable insight into the activity of other research groups or the progression of research areas as a whole.
Machine learning for drug prioritization
The drug development process is increasingly costly, leading to a pharmaceutical industry that many describe as unsustainable. Machine learning techniques have now been applied successfully in a large number of environments, and their application to predicting the success of preclinical compounds could lead to a reduction in the attrition rate and therefore dramatic improvements to the cost of drug development.
The safety and quality of digitally-delivered health interventions
Researching regulation, standards, validation, and assessment of the efficacy, effectiveness, and costs of digital health.
(Pre-) adoption and abandonment of health innovations in different settings.
Evaluating facilitators and barriers influencing the uptake of digitally-delivered interventions from the perspective of different stakeholders (patients, carers, health workers, clinics, hospitals, policy makers, regulators, insurers, pharma, start-ups, medical device, biotech and technology companies etc.).
Collaborators: Gloria Lam (DPhil student, Mechanical Engineering)
Sources of funding
UK Medical Research Council (MRC), GE Healthcare, CCRM, Sartorius Stedim Biotech (formerly TAP Biosystems), Lonza, CIRM, SENS Research Foundation, UK Cell Therapy Catapult, NIH Centre for Regenerative Medicine, NYSCF, ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche, Oxford Biomedica, Oxford NIHR BRU, the Saïd Foundation, the SENS Research Foundation, Innovate UK (formerly Technology Strategy Board), European Institute for Innovation and Technology (EIT) Health, Higher Education Funding Council for England (HEFCE), NHS England, UK Medical Research Council, European Institute for Innovation and Technology (EIT) Digital.
The Reporting Items for Patent Landscapes statement.
Smith JA. et al, (2018), Nat biotechnol, 36, 1043 - 1047
Biotechnology Governance 2.0: A Proposal for Minimum Standards in Biotechnology Corporate Governance.
Carter A. et al, (2018), Rejuvenation research
Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.
Brindley D. et al, (2018), Rejuvenation research
Bioprocess Decision Support Tool For Scalable Manufacture of Extracellular Vesicles.
Ng KS. et al, (2018), Biotechnology and bioengineering